CoChat

Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX -Mutant Cancers to WEE1 Inhibition

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

The tumor suppressor gene ATRX is frequently mutated in a variety of tumors including gliomas and liver cancers, which are highly unresponsive to current therapies. Here, we performed a genome-wide synthetic lethal screen, using CRISPR-Cas9 genome editing, to identify potential therapeutic targets specific for ATRX -mutated cancers. In isogenic hepatocellular carcinoma (HCC) cell lines engineered for ATRX loss, we identified 58 genes, including the checkpoint kinase WEE1 , uniquely required for the cell growth of ATRX null cells. Treatment with the WEE1 inhibitor AZD1775 robustly inhibited the growth of several ATRX-deficient HCC cell lines in vitro , as well as xenografts in vivo . The increased sensitivity to the WEE1 inhibitor was caused by accumulated DNA damage-induced apoptosis. AZD1775 also selectively inhibited the proliferation of patient-derived primary cell lines from gliomas with naturally occurring ATRX mutations, indicating that the synthetic lethal relationship between WEE1 and ATRX could be exploited in a broader spectrum of human tumors. As WEE1 inhibitors have been investigated in several phase II clinical trials, our discovery provides the basis for an easily clinically testable therapeutic strategy specific for cancers deficient in ATRX . SIGNIFICANCE: ATRX -mutant cancer cells depend on WEE1, which provides a basis for therapeutically targeting WEE1 in ATRX -deficient cancers. See related commentary by Cole, p. 375 .

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-18-3374

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

See all 75

Metadata

Authors
Liang, J., Zhao, H., Diplas, B. H., Liu, S., Liu, J., Wang, D., Lu, Y., Zhu, Q., Wu, J., Wang, W., Yan, H., Zeng, Y.-X., Wang, X., & Jiao, Y.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Duke University (US)
  • Sun Yat-sen University Cancer Center (CN)
Corresponding author
  • Wang, Xiaoyue
  • Jiao, Yuchen
Venue
Cancer Research
Published
2020-02-01
Volume
80
Issue
3
Pages
510-523
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2976399137
Cited by
75
References
49
Citations by year
2026: 7 · 2025: 8 · 2024: 10 · 2023: 13 · 2022: 16 · 2021: 11 · 2020: 10
FWCI
3.06
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation Fund (81472559, 81502420)
  • National Key Basic Research Program of China (2015CB553902)
  • CAMS (2017-I2M-4-003, 2017-I2M-4-002)
  • Infection Diseases of China (2017ZX10201021-007-003)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
ATRX mutation, WEE1 inhibition, AZD1775, synthetic lethality, hepatocellular carcinoma, glioma, DNA damage-induced apoptosis, drug target identification, checkpoint kinase
MeSH terms
X-linked Nuclear Protein, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Nuclear Proteins, Protein-Tyrosine Kinases, Pyrimidinones, Cell Cycle Proteins, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX -Mutant Cancers to WEE1 Inhibition. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-3374
The paper
Liang, J., Zhao, H., Diplas, B. H., Liu, S., Liu, J., Wang, D., Lu, Y., Zhu, Q., Wu, J., Wang, W., Yan, H., Zeng, Y.-X., Wang, X., & Jiao, Y. (2020). Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX -Mutant Cancers to WEE1 Inhibition. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-3374

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.